Rochester, Minnesota, and Waltham, Massachusetts, U.S., September 15, 2026
Mayo Clinic and Thermo Fisher Scientific have launched Precure, LLC, a new biomedical data initiative designed to help researchers identify early biological signs of disease before symptoms appear. The organizations said Precure will create a large-scale biomedical dataset by integrating proteomic, genomic, and longitudinal clinical data to better understand how people transition from health toward disease. The initiative is intended to generate new opportunities for early disease detection, prevention, drug development, diagnostics, and personalized treatment across conditions including cancer, cardiometabolic disease, neurological disorders, and immune-mediated diseases. Mayo Clinic will serve as the majority owner of Precure, while Thermo Fisher Scientific will participate as a minority owner.
Precure Builds Population-Scale Multi-Omics Data
A central objective of Precure is the generation and integration of molecular and clinical information at unprecedented scale. The initiative plans to analyze data generated from approximately one million biospecimens, linking molecular measurements with longitudinal clinical information collected over several years. By combining genomic and proteomic information with clinical data, researchers will be able to investigate biological changes that may occur well before conventional symptoms result in a clinical diagnosis. The organizations said that many diseases begin developing biologically years before they become clinically apparent. Precure is designed to capture these changes and create a research infrastructure capable of identifying patterns associated with disease development. The resulting dataset could provide researchers with new insights into disease biology, early biomarkers, therapeutic targets, and patient-specific disease pathways.
AI and Proteomics Drive Early Disease Research
Artificial intelligence and large-scale data analytics will be integral components of the Precure initiative. Researchers will use computational approaches to analyze complex molecular datasets and identify patterns that may be difficult to recognize through conventional analysis. These approaches are expected to support the translation of large-scale biological data into insights that could eventually contribute to new diagnostic and therapeutic strategies. Thermo Fisher Scientific will contribute its expertise in proteomics and analytical technologies, including the Olink Explore HT proteomics platform and Thermo Scientific Orbitrap Mass Spectrometry, along with associated kits and reagents. Mayo Clinic will contribute its clinical and research expertise, biospecimens, longitudinal de-identified clinical data, and capabilities in AI and data science. The combination is intended to create a standardized environment for generating and integrating molecular and clinical information.
Advertisement
Accelerating Diagnostics and Therapeutic Discovery
Precure is intended not simply as a data-generation project but as an infrastructure for translating discoveries into potential healthcare applications. By identifying molecular changes that precede clinical symptoms, researchers could gain a better understanding of how diseases emerge and progress. This information may help support the development of earlier diagnostic approaches, new therapeutic targets, more precise treatments, and disease-prevention strategies. The initiative complements Precure Research, Mayo Clinic’s investigator-led effort focused on understanding biological changes associated with the transition from health to disease. While Precure Research advances scientific investigation into early disease signals, Precure, LLC is designed to provide the scale, infrastructure, and collaborations needed to generate population-level molecular data and help translate discoveries into diagnostics, therapeutics, and other healthcare solutions. Mayo Clinic will provide pathways for validating discoveries and potentially translating meaningful findings into patient care.
The launch reflects the growing role of multi-omics, AI, proteomics, and longitudinal clinical data in modern biomedical research. Instead of relying solely on information collected after symptoms appear, researchers are increasingly investigating molecular changes that may signal disease much earlier. Through its planned integration of one million biospecimens with clinical information, Precure aims to create a foundation for large-scale research into disease mechanisms and early intervention. For pharmaceutical and biotechnology researchers, the resulting insights could potentially support target discovery, biomarker development, clinical research, and drug-development programs across multiple therapeutic areas.
Source: Mayo Clinic, Thermo Fisher Scientific press release
